Clinical Trials Logo
  1. Home
  2. Uterine Cancer
  3. NCT03668340

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Uterine Cancer Clinical Trial

Official title:
A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Clinical Trial Summary

This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775

Clinical Trial Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved AZD1775 as a treatment for any disease. The "investigational drug" AZD1775 is being given alone to patients with this type of cancer. AZD1775 is also being studied in lung cancer, ovarian cancer, and other solid tumors throughout the world. AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked. This study is being done to assess the safety and effectiveness of AZD1775 to learn if AZD1775 works in treating this type of cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03668340
Study type Interventional
Source Dana-Farber Cancer Institute
Contact
Status Active, not recruiting
Phase Phase 2
Start date October 22, 2018
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT03285802 - Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Phase 2/Phase 3
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Not yet recruiting NCT06369155 - Azenosertib in Uterine Serous Carcinoma: Biomarker Study Phase 2
Not yet recruiting NCT05998811 - Insights Into Participating in Studies for Uterine Cancer
Completed NCT01399658 - Image-Guided Gynecologic Brachytherapy Phase 2
Completed NCT01432015 - Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Phase 4
Recruiting NCT02349958 - Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Phase 2
Completed NCT00581646 - Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance N/A
Completed NCT00284427 - Safety of Antioxidants During GYN Cancer Care Phase 2
Completed NCT00147680 - Uterine Papillary Serous Cancer (UPSC) Trial Phase 2
Recruiting NCT05743517 - Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) N/A
Recruiting NCT05916196 - [18F]FES PET/.CT in Uterine Cancer Phase 2
Withdrawn NCT04368130 - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care N/A
Completed NCT00588640 - Study of D-Methadone in Patients With Chronic Pain Phase 1/Phase 2
Recruiting NCT05990426 - Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy N/A
Completed NCT03701529 - Effect of Anesthetic Agents on Optic Nerve Sheath Diameter N/A
Recruiting NCT05758688 - Whole Pelvis Proton Radiation for Gynecologic Cancer N/A
Completed NCT01953107 - Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Phase 4
Completed NCT01709175 - Strength Training Study for Survivors of Breast and Gynecologic Cancer N/A